{"id":2046,"date":"2026-06-24T20:15:00","date_gmt":"2026-06-24T20:15:00","guid":{"rendered":"https:\/\/cielcharlotte.com\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes\/"},"modified":"2026-06-24T20:15:00","modified_gmt":"2026-06-24T20:15:00","slug":"cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes","status":"publish","type":"post","link":"https:\/\/development.brstdev.com\/cielcharlotte\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes\/","title":{"rendered":"CIR-0602K Begins Dosing in Breakthrough T1D-Supported Phase 2 in Type 1 Diabetes"},"content":{"rendered":"

Randomized placebo-controlled studyAssessing 3 months of CIR-0602K for increasing glucose time-in-range, reducing HbA1c and total daily insulin dose, and improving cardiovascular biomarkers and vascular functionSupported by Breakthrough T1D and ongoing at University of Virginia School of MedicineTopline data\u2026<\/p>\n

Read the full release \u2192<\/a><\/p>\n

News provided by PR Newswire.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Randomized placebo-controlled studyAssessing 3 months of CIR-0602K for increasing glucose time-in-range, reducing HbA1c and total daily insulin dose, and improving cardiovascular biomarkers and vascular functionSupported by Breakthrough T1D and ongoing at University of Virginia School of MedicineTopline data\u2026<\/p>\n","protected":false},"author":14,"featured_media":2048,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-2046","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-art-community"],"yoast_head":"\nCIR-0602K Begins Dosing in Breakthrough T1D-Supported Phase 2 in Type 1 Diabetes - Ciel Charlotte<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CIR-0602K Begins Dosing in Breakthrough T1D-Supported Phase 2 in Type 1 Diabetes - Ciel Charlotte\" \/>\n<meta property=\"og:description\" content=\"Randomized placebo-controlled studyAssessing 3 months of CIR-0602K for increasing glucose time-in-range, reducing HbA1c and total daily insulin dose, and improving cardiovascular biomarkers and vascular functionSupported by Breakthrough T1D and ongoing at University of Virginia School of MedicineTopline data\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/development.brstdev.com\/cielcharlotte\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes\/\" \/>\n<meta property=\"og:site_name\" content=\"Ciel Charlotte\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-24T20:15:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/default-image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"384\" \/>\n\t<meta property=\"og:image:height\" content=\"253\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Ethan Parker\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ethan Parker\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes\\\/\"},\"author\":{\"name\":\"Ethan Parker\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#\\\/schema\\\/person\\\/4c5e38434c81d2ebb9c5787b29251450\"},\"headline\":\"CIR-0602K Begins Dosing in Breakthrough T1D-Supported Phase 2 in Type 1 Diabetes\",\"datePublished\":\"2026-06-24T20:15:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes\\\/\"},\"wordCount\":61,\"image\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes-ai.png\",\"articleSection\":[\"Art Community\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes\\\/\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes\\\/\",\"name\":\"CIR-0602K Begins Dosing in Breakthrough T1D-Supported Phase 2 in Type 1 Diabetes - Ciel Charlotte\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes-ai.png\",\"datePublished\":\"2026-06-24T20:15:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#\\\/schema\\\/person\\\/4c5e38434c81d2ebb9c5787b29251450\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes\\\/#primaryimage\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes-ai.png\",\"contentUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes-ai.png\",\"width\":1536,\"height\":1024,\"caption\":\"CIR-0602K Begins Dosing in Breakthrough T1D-Supported Phase 2 in Type 1 Diabetes\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CIR-0602K Begins Dosing in Breakthrough T1D-Supported Phase 2 in Type 1 Diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#website\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/\",\"name\":\"Ciel Charlotte\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#\\\/schema\\\/person\\\/4c5e38434c81d2ebb9c5787b29251450\",\"name\":\"Ethan Parker\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/ethan-parkar-96x96.jpeg\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/ethan-parkar-96x96.jpeg\",\"contentUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/ethan-parkar-96x96.jpeg\",\"caption\":\"Ethan Parker\"},\"description\":\"Ethan Parker covers stories about community life, personal well-being, local initiatives, lifestyle trends, and the people working to create stronger communities. His writing looks for the human element behind larger developments, focusing on practical ideas and meaningful stories. Ethan brings an approachable perspective to subjects involving everyday life, community participation, creativity, and social connection.\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/author\\\/ethan-parker\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CIR-0602K Begins Dosing in Breakthrough T1D-Supported Phase 2 in Type 1 Diabetes - Ciel Charlotte","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"CIR-0602K Begins Dosing in Breakthrough T1D-Supported Phase 2 in Type 1 Diabetes - Ciel Charlotte","og_description":"Randomized placebo-controlled studyAssessing 3 months of CIR-0602K for increasing glucose time-in-range, reducing HbA1c and total daily insulin dose, and improving cardiovascular biomarkers and vascular functionSupported by Breakthrough T1D and ongoing at University of Virginia School of MedicineTopline data\u2026","og_url":"https:\/\/development.brstdev.com\/cielcharlotte\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes\/","og_site_name":"Ciel Charlotte","article_published_time":"2026-06-24T20:15:00+00:00","og_image":[{"width":384,"height":253,"url":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/default-image.jpg","type":"image\/jpeg"}],"author":"Ethan Parker","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ethan Parker"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes\/#article","isPartOf":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes\/"},"author":{"name":"Ethan Parker","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#\/schema\/person\/4c5e38434c81d2ebb9c5787b29251450"},"headline":"CIR-0602K Begins Dosing in Breakthrough T1D-Supported Phase 2 in Type 1 Diabetes","datePublished":"2026-06-24T20:15:00+00:00","mainEntityOfPage":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes\/"},"wordCount":61,"image":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes\/#primaryimage"},"thumbnailUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/06\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes-ai.png","articleSection":["Art Community"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes\/","url":"https:\/\/development.brstdev.com\/cielcharlotte\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes\/","name":"CIR-0602K Begins Dosing in Breakthrough T1D-Supported Phase 2 in Type 1 Diabetes - Ciel Charlotte","isPartOf":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#website"},"primaryImageOfPage":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes\/#primaryimage"},"image":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes\/#primaryimage"},"thumbnailUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/06\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes-ai.png","datePublished":"2026-06-24T20:15:00+00:00","author":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#\/schema\/person\/4c5e38434c81d2ebb9c5787b29251450"},"breadcrumb":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/development.brstdev.com\/cielcharlotte\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes\/#primaryimage","url":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/06\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes-ai.png","contentUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/06\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes-ai.png","width":1536,"height":1024,"caption":"CIR-0602K Begins Dosing in Breakthrough T1D-Supported Phase 2 in Type 1 Diabetes"},{"@type":"BreadcrumbList","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/cir-0602k-begins-dosing-in-breakthrough-t1d-supported-phase-2-in-type-1-diabetes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/development.brstdev.com\/cielcharlotte\/"},{"@type":"ListItem","position":2,"name":"CIR-0602K Begins Dosing in Breakthrough T1D-Supported Phase 2 in Type 1 Diabetes"}]},{"@type":"WebSite","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#website","url":"https:\/\/development.brstdev.com\/cielcharlotte\/","name":"Ciel Charlotte","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/development.brstdev.com\/cielcharlotte\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#\/schema\/person\/4c5e38434c81d2ebb9c5787b29251450","name":"Ethan Parker","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/ethan-parkar-96x96.jpeg","url":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/ethan-parkar-96x96.jpeg","contentUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/ethan-parkar-96x96.jpeg","caption":"Ethan Parker"},"description":"Ethan Parker covers stories about community life, personal well-being, local initiatives, lifestyle trends, and the people working to create stronger communities. His writing looks for the human element behind larger developments, focusing on practical ideas and meaningful stories. Ethan brings an approachable perspective to subjects involving everyday life, community participation, creativity, and social connection.","url":"https:\/\/development.brstdev.com\/cielcharlotte\/author\/ethan-parker\/"}]}},"_links":{"self":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts\/2046","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/comments?post=2046"}],"version-history":[{"count":1,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts\/2046\/revisions"}],"predecessor-version":[{"id":9517,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts\/2046\/revisions\/9517"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/media\/2048"}],"wp:attachment":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/media?parent=2046"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/categories?post=2046"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/tags?post=2046"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}